Paradigm’s strategic management is driven by a team with significant experience in drug development and the execution of clinical studies.

Executive Leadership Team

Our Chief Executive Officer, Mr Paul Rennie, has been involved in drug development and a number of pre-clinical and clinical trial programs (was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd). Mr. Rennie has extensive experience in commercialising Intellectual Property.

Our Chief Scientific Officer, Dr Ravi Krishnan, is a basic scientist with a long-standing interest and experience in experimental pathology, transplantation immunology, gene and stem cell therapy. He has also had significant experience in investigating novel compounds with immune modulatory effects, anti-inflammatory and anti-angiogenic properties.

Director of Investor Relations, Simon White, joined the Paradigm team in January 2020. Simon has a wide range of experience in the financial services sector, with previous roles including Corporate Advisory at DELCOR, a Melbourne based Family Office, and Institutional Sales at Sequoia Wealth Management.  As a former AFL footballer for Carlton, Simon brings a unique combination of skills. Having spent 8 years as a high-performing professional athlete, Simon’s team-orientated approach and networking skills make a highly valuable contribution to the team.

Our Global Head of Regulatory Affairs, Michelle Coffey, has over 20 years global experience in the pharmaceutical industry (Chemical and Biological), covering the life cycle of a product from early stage clinical right through to commercial launch and maintenance.  She has extensive knowledge in global regulatory requirements, working on areas including emerging treatments and clinical protocols for cell therapy products and technologies. She has worked on cross-functional teams in order to develop effective product strategy, and ensure submission timelines and global regulatory requirements are met.

Senior management

Our Clinical Operations Director of Osteoarthritis, Melanie Duiker, joined the Paradigm team in 2017. With over 25 years of experience in clinical research, she is responsible for the coordination and oversight of our clinical research activities within Australia and abroad. Her industry experience includes managing clinical operations at local, as well as international level, with 8 years managing clinical operations with Europe.  Melanie brings broad experience in clinical study development and operations, including Feasibility, Forecasting and budget management, Quality Management, Audit Management, and Vendor Management.

Our Clinical Operations Lead, Jill Forrest, has over 30 years’ experience working in healthcare, with 20 years in the clinical research industry. Her experience in clinical research ranges from working as a study coordinator, clinical research associate and clinical research consultant across phase I-III trials. Jill has worked at world leading pharmaceutical companies, including Pfizer and AstraZeneca, and brings with her a broad understanding of project and site management.

Our Chief Medical Officer, Dr.Donna Skerrett, joined the Paradigm team in September 2019. With more than 30 years’ experience in transfusion medicine, cellular therapy, and transplantation, she brings a wealth of experience in medical, clinical, and regulatory affairs. Donna served previously as Chief Medical Officer at Mesoblast. She was Director of Transfusion Medicine and Cellular Therapy at Weill Cornell Medical Center in New York (2004 – 2011), and prior to that was Associate Director of Transfusion Medicine and Director of Stem Cell Facilities at Columbia University’s New York-Presbyterian Hospital.  She previously chaired the New York State Council on Blood and Transfusion Services and currently serves on the Board of Directors of the Fox Chase Cancer Center in Philadelphia, Pa.

Our Chief Operating Officer, Dr Jeannie Joughin, joined the Paradigm team in June 2020. During almost 9 years in the US she held senior executive roles with Enable Injections and CSL Behring. Upon her return to Australia early 2019, Jeannie provided ongoing leadership support to Enable Injections, joined an unlisted public company as Non-Executive Director and was a principal commercial advisor to Australian biotechnology and medical technology companies. She is an experienced biopharmaceutical and medical device leader with over 20 years’ experience in global biopharmaceutical companies and start-up environments. Her responsibilities and experience have included extensive post-doctoral research, clinical trial management, brand management, licensing and business development, team leadership, and strategic planning.

Our CFO and Company Secretary, Mr. Kevin Hollingsworth, Kevin Hollingsworth, FCPA, FCMA, CGMA, in addition to his duties at Paradigm, serves as Principal of Hollingsworth Financial Services. Prior to that, he served as Chief Financial Officer and Company Secretary of Mesoblast Limited (ASX: MSB). At Alpha Technologies Corporation Limited (ASX: ASU), Kevin Hollingsworth served as a Non-Executive Director. He is a Chartered Global Management Accountant and Fellow of CPA Australia and Chartered Management Accountants.

Our Clinical Development Director, Sharon Charles, has over 30 years’ experience in the healthcare sector across geographies, with 24 years in clinical and commercial development. She has a strong track record in developing world-class products and services and growing regional business. Sharon has worked at world leading biotech companies, including Amgen and CSL, and brings a depth of biotech development understanding and skill.

Our Associate Director of Regulatory Affairs, Karla Knower (PhD), has extensive knowledge in managing global Regulatory strategies and submissions for diverse product portfolios. Karla’s expertise spans across the progressive stages of product development, from R&D through to marketed products and life-cycle maintenance. Karla has delivered regulatory oversight on the conduct of Phase II, Phase III, and Pivotal Clinical trials both in the USA and in the Europe. It is through these processes that Karla’s regulatory intelligence has broadened and strengthened to set up a solid foundation for well-considered, tactically planned regulatory filings for the advancement of clinical development plans.